X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (73765) 73765
Book Chapter (280) 280
Newsletter (252) 252
Magazine Article (182) 182
Book / eBook (102) 102
Newspaper Article (79) 79
Dissertation (29) 29
Web Resource (25) 25
Conference Proceeding (21) 21
Transcript (15) 15
Reference (14) 14
Publication (10) 10
Book Review (8) 8
Report (3) 3
Streaming Video (2) 2
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (57979) 57979
female (26415) 26415
animals (26361) 26361
male (25616) 25616
recombinant proteins - therapeutic use (20675) 20675
recombinant proteins (19089) 19089
middle aged (15684) 15684
adult (15122) 15122
mice (13246) 13246
aged (10079) 10079
treatment outcome (9048) 9048
proteins (8116) 8116
interferon-alpha - therapeutic use (7983) 7983
immunology (7873) 7873
oncology (7227) 7227
expression (6389) 6389
hematology (6261) 6261
biotechnology & applied microbiology (5965) 5965
pharmacology & pharmacy (5915) 5915
therapy (5588) 5588
medicine, research & experimental (5570) 5570
recombinant proteins - metabolism (5351) 5351
antiviral agents - therapeutic use (5264) 5264
biochemistry & molecular biology (5237) 5237
research (5204) 5204
health aspects (5160) 5160
recombinant proteins - genetics (4982) 4982
recombinant proteins - administration & dosage (4938) 4938
erythropoietin - therapeutic use (4920) 4920
analysis (4875) 4875
cancer (4825) 4825
recombinant proteins - pharmacology (4815) 4815
drug therapy, combination (4625) 4625
adolescent (4543) 4543
rats (4437) 4437
time factors (4352) 4352
recombinant fusion proteins - therapeutic use (4241) 4241
gene expression (4202) 4202
care and treatment (4088) 4088
research article (3619) 3619
cell biology (3599) 3599
polyethylene glycols - therapeutic use (3558) 3558
hepatitis c, chronic - drug therapy (3520) 3520
ribavirin - therapeutic use (3513) 3513
recombinant fusion proteins - genetics (3450) 3450
dose-response relationship, drug (3406) 3406
cells (3391) 3391
child (3382) 3382
recombinant proteins - adverse effects (3272) 3272
recombinant proteins - chemistry (3247) 3247
disease models, animal (3219) 3219
multidisciplinary sciences (3191) 3191
antibodies (3179) 3179
immunotherapy (3170) 3170
cell line (3079) 3079
mice, inbred c57bl (3062) 3062
medicine (3020) 3020
molecular sequence data (3007) 3007
mice, inbred balb c (2975) 2975
surgery (2972) 2972
gastroenterology & hepatology (2941) 2941
amino acid sequence (2910) 2910
interferon (2909) 2909
biotechnology (2886) 2886
physiological aspects (2862) 2862
recombinant fusion proteins - metabolism (2809) 2809
microbiology (2775) 2775
in-vivo (2734) 2734
recombinant proteins - immunology (2724) 2724
vaccines (2673) 2673
cells, cultured (2666) 2666
cell line, tumor (2637) 2637
retrospective studies (2629) 2629
protein (2592) 2592
apoptosis (2551) 2551
prospective studies (2440) 2440
transplantation (2414) 2414
aged, 80 and over (2410) 2410
infection (2410) 2410
antigens (2374) 2374
antibodies, monoclonal - therapeutic use (2367) 2367
antineoplastic combined chemotherapy protocols - therapeutic use (2341) 2341
erythropoietin (2341) 2341
interferon-alpha - administration & dosage (2332) 2332
follow-up studies (2300) 2300
recombinant proteins - biosynthesis (2290) 2290
genetic aspects (2287) 2287
drug administration schedule (2286) 2286
enzymes (2282) 2282
medicine, general & internal (2270) 2270
infectious diseases (2251) 2251
clinical trials as topic (2245) 2245
anemia - drug therapy (2234) 2234
antineoplastic agents - therapeutic use (2223) 2223
anemia (2211) 2211
science (2200) 2200
drug therapy (2184) 2184
risk factors (2152) 2152
biology (2146) 2146
peptides (2133) 2133
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (42) 42
Online Resources - Online (28) 28
UofT at Mississauga - Stacks (12) 12
Collection Dvlpm't (Acquisitions) - Vendor file (10) 10
Collection Dvlpm't (Acquisitions) - Closed Orders (9) 9
Engineering & Comp. Sci. - Stacks (8) 8
UTL at Downsview - May be requested (2) 2
UofT at Scarborough - Stacks (2) 2
Earth Sciences (Noranda) - Stacks (1) 1
Gerstein Science - Searching (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
UofT at Mississauga - Not Returned (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (71827) 71827
Japanese (681) 681
German (657) 657
French (627) 627
Chinese (599) 599
Spanish (490) 490
Russian (349) 349
Italian (177) 177
Polish (170) 170
Portuguese (124) 124
Dutch (73) 73
Hungarian (61) 61
Czech (48) 48
Serbian (38) 38
Bulgarian (25) 25
Korean (25) 25
Croatian (23) 23
Danish (23) 23
Finnish (20) 20
Hebrew (18) 18
Norwegian (18) 18
Ukrainian (17) 17
Slovak (15) 15
Swedish (13) 13
Turkish (7) 7
Romanian (6) 6
Lithuanian (4) 4
Arabic (3) 3
Persian (3) 3
Bosnian (2) 2
Icelandic (1) 1
Nauru (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Treatment Reviews, ISSN 0305-7372, 2014, Volume 40, Issue 9, pp. 1080 - 1088
Highlights • PTCL has a poor prognosis; existing therapies are insufficient. • We summarize current evidence on novel therapies for relapsed/refractory PTCL. •... 
Hematology, Oncology and Palliative Medicine | Antifolate | Nucleoside analog | Histone deacetylase inhibitor | Fusion protein | Peripheral T-cell lymphoma | Immunomodulatory agent | DENILEUKIN DIFTITOX | NON-HODGKINS-LYMPHOMAS | FOLLOW-UP | BRENTUXIMAB VEDOTIN SGN-35 | OPEN-LABEL | ALLOGENEIC TRANSPLANTATION | SINGLE-AGENT | PHASE-II TRIAL | ONCOLOGY | SALVAGE THERAPY | HIGH-DOSE CHEMOTHERAPY | Doxorubicin - therapeutic use | Humans | Recombinant Fusion Proteins - therapeutic use | Interleukin-2 - therapeutic use | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - therapeutic use | Cyclophosphamide - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Folic Acid Antagonists - therapeutic use | Stem Cell Transplantation | Topoisomerase Inhibitors - pharmacology | Thalidomide - analogs & derivatives | Diphtheria Toxin - therapeutic use | Topoisomerase Inhibitors - therapeutic use | Immunoconjugates - therapeutic use | Antineoplastic Agents - pharmacology | Depsipeptides - therapeutic use | Prednisolone - therapeutic use | Lymphoma, T-Cell, Peripheral - drug therapy | Antibodies, Monoclonal, Humanized - therapeutic use | Alemtuzumab | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, T-Cell, Peripheral - pathology | Vincristine - therapeutic use | Histone Deacetylase Inhibitors - therapeutic use | Lymphoma, T-Cell, Peripheral - therapy | Thalidomide - therapeutic use | Folic Acid Antagonists - pharmacology | Care and treatment | Lymphomas | T cells | Health aspects
Journal Article
2010, 1. Aufl., ISBN 0470411961, xxii, 486
.... Aggregation of Therapeutic Proteins provides an up-to-date resource on protein aggregation and its consequences, and available methods to control or slow down the aggregation process... 
Cell Aggregation | Protein Conformation | metabolism | Aggregation (Chemistry) | Recombinant Proteins | therapeutic use | Protein drugs | Protein Folding | Development | Pharmacology | Drug Discovery | MEDICAL
Book
Thrombosis and Haemostasis, ISSN 0340-6245, 09/2015, Volume 113, Issue 5, pp. 931 - 942
Summary Several new anticoagulants have entered the clinical arena or are under clinical development. These drugs include indirect (fondaparinux) and direct... 
Review Article | Rivaroxaban | Antidotes | Dabigatran | New anticoagulants | Apixaban | ANDEXANET-ALPHA | VITAMIN-K ANTAGONISTS | rivaroxaban | apixaban | ATRIAL-FIBRILLATION | antidotes | IN-VITRO | ANTIIDIOTYPIC ANTIBODIES | PROTHROMBIN COMPLEX CONCENTRATE | ORAL ANTICOAGULANTS | MOLECULAR-WEIGHT HEPARIN | dabigatran | PERIPHERAL VASCULAR DISEASE | HEALTHY-VOLUNTEERS | HEMATOLOGY | ACUTE VENOUS THROMBOEMBOLISM | Recombinant Proteins - therapeutic use | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | Thrombosis - complications | Humans | Antibodies, Monoclonal - therapeutic use | Heparin - therapeutic use | Hemorrhage - prevention & control | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Vitamin K - antagonists & inhibitors | Benzamides - therapeutic use | Anticoagulants - chemistry | Factor Xa - therapeutic use | Intracranial Hemorrhages - prevention & control | Rivaroxaban - therapeutic use | Pyridines - therapeutic use | Polysaccharides - therapeutic use | Hemostatics - chemistry | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Infusions, Parenteral | Clinical Trials as Topic | Factor Xa Inhibitors - therapeutic use | Animals | Protamines - therapeutic use | Pyridones - therapeutic use | Thrombosis - drug therapy | Hemorrhage - chemically induced | Hemostatics - therapeutic use
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 07/2016, Volume 134, Issue 3, pp. 248 - 261
Vitamin K antagonists are commonly used by clinicians to provide anticoagulation to patients who have or are at risk of having thrombotic events. In addition... 
anticoagulants | atrial fibrillation | venous thromboembolism | hemorrhage | CARDIAC & CARDIOVASCULAR SYSTEMS | ACTIVATED FACTOR-VII | ATRIAL-FIBRILLATION | IN-VITRO | THROMBIN GENERATION | DABIGATRAN ETEXILATE | PROTHROMBIN COMPLEX CONCENTRATE | SYMPTOMATIC VENOUS THROMBOEMBOLISM | PRACTICAL MANAGEMENT | PERIPHERAL VASCULAR DISEASE | STAGE RENAL-DISEASE | FACTOR XA INHIBITOR | Recombinant Proteins - therapeutic use | Plasma | Dabigatran - adverse effects | Pyrazoles - therapeutic use | Humans | Hemorrhage - prevention & control | Recombinant Proteins - adverse effects | Thiazoles - therapeutic use | Factor VIIa - therapeutic use | Arginine - analogs & derivatives | Dabigatran - therapeutic use | Thiazoles - adverse effects | Pyridines - adverse effects | Rivaroxaban - adverse effects | Factor Xa - therapeutic use | Rivaroxaban - therapeutic use | Factor Xa - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Piperazines - therapeutic use | Dabigatran - antagonists & inhibitors | Piperazines - adverse effects | Factor Xa Inhibitors - therapeutic use | Hemorrhage - drug therapy | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Blood Coagulation Factors - therapeutic use | Arginine - adverse effects | Pyridones - therapeutic use | Hemorrhage - chemically induced | Hemostatics - therapeutic use | Arginine - therapeutic use | Pyridones - adverse effects
Journal Article
BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, ISSN 1173-8804, 2010, Volume 24, Issue 1, pp. 9 - 21
Journal Article
2012, 3rd ed., Methods in molecular biology, ISBN 9781617794322, Volume 824., xvi, 649
Book
Science (American Association for the Advancement of Science), ISSN 1095-9203, 2011, Volume 332, Issue 6028, pp. 478 - 484
.... Atsttrin, an engineered protein composed of three PGRN fragments, exhibited selective TNFR binding... 
Cartilage | Immunization | Antiinflammatories | Medical treatment | REPORTS | Collagens | Antibodies | Bones | Arthritis | Mice | Inflammation | TUMOR-NECROSIS-FACTOR | GENE | MULTIDISCIPLINARY SCIENCES | HOST-DEFENSE | DEGRADATION | OLIGOMERIC MATRIX PROTEIN | GRANULIN-EPITHELIN PRECURSOR | ADAMTS-7 | MUTATIONS | TRANSCRIPTION FACTOR | PSEUDOACHONDROPLASIA | Recombinant Proteins - therapeutic use | Tumor Necrosis Factor-alpha - metabolism | Arthritis, Experimental - drug therapy | Recombinant Fusion Proteins - pharmacology | Humans | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Intercellular Signaling Peptides and Proteins - chemistry | Male | Receptors, Tumor Necrosis Factor, Type I - metabolism | Recombinant Fusion Proteins - metabolism | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | T-Lymphocytes, Regulatory - immunology | Arthritis, Experimental - pathology | Young Adult | Intercellular Signaling Peptides and Proteins - metabolism | Cartilage, Articular - metabolism | Receptors, Tumor Necrosis Factor, Type II - metabolism | Adult | Female | Protein Interaction Domains and Motifs | Anti-Inflammatory Agents, Non-Steroidal - metabolism | T-Lymphocytes, Regulatory - physiology | Arthritis, Experimental - physiopathology | Signal Transduction | Intercellular Signaling Peptides and Proteins - genetics | Mice, Transgenic | Arthritis, Experimental - immunology | Mice, Inbred Strains | Receptors, Tumor Necrosis Factor, Type I - genetics | Receptors, Tumor Necrosis Factor, Type II - genetics | Mice, Knockout | Cartilage, Articular - pathology | Animals | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Adolescent | Ligands | Aged | Intercellular Signaling Peptides and Proteins - therapeutic use | Care and treatment | Genetic aspects | Properties | Tumor necrosis factor | Growth factors
Journal Article